Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.

To explore the safety and synergy of the proposed combinatorial approach, participants with locally advanced PC will receive nivolumab and ipilimumab administered in combination with gemcitabine and nab-paclitaxel followed by immune-chemoradiation.

chemotherapy regimen
nivolumab
pancreatic ductal adenocarcinoma
immunosuppressive agents
paclitaxel
  • 0 views
  • 19 Feb, 2024
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC and to assess the T-cell response.

nivolumab
cancer
peptide vaccine
measurable disease
core needle biopsy
  • 0 views
  • 19 Feb, 2024
Intratumoral Tilsotolimod a TLR-9 Agonist Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

Open label, phase Ib study of intratumoral tilsotolimod in combination with intratumoral ipilimumab and intravenous nivolumab. The trial will be divided into two parts: PART A: the first part will assess the safety of two regimen and will recruit patients with all types of injectable solid malignancies PART B: the …

nivolumab
metastatic melanoma
cancer treatment
advanced cancer
colorectal cancer
  • 0 views
  • 19 Feb, 2024
PHP and Immunotherapy in Metastasized UM

It usually disseminates rapidly throughout the body, most commonly to the liver and lungs. In this study a combination therapy with immunotherapy (ipilimumab with nivolumab) and chemotherapy (melphalan) will be assessed for the treatment of disseminated uveal melanoma. Melphalan will be administered selectively to the liver via percutaneous hepatic perfusion, …

  • 0 views
  • 19 Feb, 2024
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.

ras-gef
metastatic melanoma
adjuvant
measurable disease
solid neoplasm
  • 0 views
  • 19 Feb, 2024
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.

renal function
nivolumab
biological therapy
myelosuppressive chemotherapy
monoclonal protein
  • 0 views
  • 19 Feb, 2024